Immunotherapy combo aims to shrink colon tumors before surgery
NCT ID NCT07224022
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two immunotherapy drugs, cemiplimab and fianlimab, can safely shrink colon tumors before surgery in people with stage II-III colon cancer that hasn't spread. Participants get two IV doses before surgery, then are followed for up to three years. The goal is to see if this approach is feasible and safe, with side effects like fatigue, rash, and immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can artificial intelligence think like a cancer tumor board?
- A new clue in the fight against colorectal cancer recurrence?
- Can radiation plus immunotherapy make colon tumors disappear before surgery?
- Can a chemo boost outsmart lingering colon cancer cells?
- Does practice make perfect? a study probes how a Surgeon's learning curve impacts cancer surgery success